Washington-The American Lithotripsy Society (ALS) and the UrologySociety of America (USA) have successfully challenged the Stark II FinalRule designating lithotripsy a "designated health service." Accordingto a summary judgment released July 16 by the U.S. District Court in Washington,lithotripsy services were never intended to be encompassed within physicianself-referrals for "inpatient and outpatient hospital services"subject to the Stark II ban.
Study links PARP inhibitors to increased risk of hematologic toxicity in mCRPC patients
November 23rd 2023A recently published study found an association between PARP inhibitor treatment and an increased risk of hematological adverse events, including anemia, thrombocytopenia, and neutropenia, in patients with metastatic castration-resistant prostate cancer.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Bone scans overstage prostate cancer vs PSMA-PET in initial setting
November 21st 2023"Rather than receiving definitive radiation treatment for localized disease, these patients may have received treatment aimed at preventing the further spread of what was incorrectly identified as metastatic disease," says Thomas Hope, MD.
2 Clarke Drive
Cranbury, NJ 08512